Highlights

  • Jefferies revises Aveanna’s rating to Buy, price target set at USD6 from USD6.25
  • Analyst anticipates positive earnings surprises due to improved capacity and contract reimbursement
  • Medicare home health exposure viewed as limited, recent stock selloff seen as excessive

Jefferies has upgraded Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) from Hold to Buy while marginally lowering its price target to USD6 from USD6.25, according to a recent note issued ahead of the company’s upcoming second-quarter earnings report. Despite a modest downward adjustment in valuation, the firm’s updated stance reflects a shift in outlook based on operational momentum and anticipated earnings upside.

In recent weeks, AVAH shares came under pressure following a proposed rate adjustment for Medicare home nursing services. However, Jefferies believes the market reaction has been disproportionate. The firm notes that Medicare home health comprises only a relatively small part of Aveanna’s overall revenue mix, making the impact of the rate change more muted than perceived.

The rating revision also signals that Jefferies expects fundamental stability in the company’s performance, supported by internal strategic adjustments. While the price target revision suggests a cautious approach, the Buy recommendation indicates confidence in the stock's relative undervaluation following its recent decline.

Aveanna’s Q2 earnings report will be a key milestone for investors assessing the credibility of these forecasts. The market will be watching for any signs of margin recovery, patient volume growth, or positive trends in payer mix—all of which could either validate or challenge the current analyst expectations.